Research programme: immunomodulators - ChemoCentryxAlternative Names: Chemokine-based immunomodulators - ChemoCentryx; Peptide immunostimulants - ChemoCentryx; ProDendryx
Latest Information Update: 24 Jul 2007
At a glance
- Originator ChemoCentryx
- Class Small molecules
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Infections
Most Recent Events
- 15 Oct 2003 Preclinical trials in Infections in USA (unspecified route)